Cargando…

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia

CD19-directed chimeric antigen receptor-T (CAR-T) cells with a 4-1BB or CD28 co-stimulatory domain have shown impressive antitumor activity against relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). However, a parallel comparison of their performances in r/r B-ALL therapy has no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiangyu, Yang, Junfang, Zhang, Xian, Lu, Xin-An, Xiong, Min, Zhang, Jianping, Zhou, Xiaosu, Qi, Feifei, He, Ting, Ding, Yanping, Hu, Xuelian, De Smet, Floris, Lu, Peihua, Huang, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378699/ https://www.ncbi.nlm.nih.gov/pubmed/32728615 http://dx.doi.org/10.1016/j.omto.2020.06.016

Ejemplares similares

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Yang, Junfang, et al.
Publicado: (2023)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
por: Ying, Zhitao, et al.
Publicado: (2022)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
por: Yang, Junfang, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
por: Zhao, Yu, et al.
Publicado: (2022)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
por: Pei, Kunlin, et al.
Publicado: (2023)

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
por: Zhang, Xian, et al.
Publicado: (2023)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
Publicado: (1991)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
por: Ma, Haili, et al.
Publicado: (2017)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
por: Textor, Ana, et al.
Publicado: (2021)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
por: Roselli, Emiliano, et al.
Publicado: (2021)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
por: Wu, Lijuan, et al.
Publicado: (2023)

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Correction: 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Publicado: (2020)

ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation
por: Rohrs, Jennifer A., et al.
Publicado: (2020)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
por: Yang, Fei, et al.
Publicado: (2019)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells
Publicado: (1992)

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
por: Blaeschke, Franziska, et al.
Publicado: (2022)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tjrq9bajjkj4713jepurtl9qko